Evidence map›Paper›PMID 36168391›Full record

ArticleiScience2022

Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern.

Peifang Sun, Irene Ramos, Camila H Coelho, Alba Grifoni, Corey A Balinsky, Sindhu Vangeti, Alison Tarke, Nathaniel I Bloom, Vihasi Jani, Silvia J Jakubski and 16 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 5 institutions in 2 countries.

Peifang SunNaval Medical Research Center, Silver Spring, MD, USA.
Irene RamosIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Camila H CoelhoLa Jolla Institute for Immunology, La Jolla, CA, USA.
Alba GrifoniLa Jolla Institute for Immunology, La Jolla, CA, USA.
Corey A BalinskyNaval Medical Research Center, Silver Spring, MD, USA.
Sindhu VangetiIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Alison TarkeLa Jolla Institute for Immunology, La Jolla, CA, USA.
Nathaniel I BloomLa Jolla Institute for Immunology, La Jolla, CA, USA.
Vihasi JaniNaval Medical Research Center, Silver Spring, MD, USA.
Silvia J JakubskiHenry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
David A BoulifardHenry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Elizabeth CooperNaval Medical Research Center, Silver Spring, MD, USA.
Carl W GoforthNaval Medical Research Center, Silver Spring, MD, USA.
Jan MarayagNaval Medical Research Center, Silver Spring, MD, USA.
Amethyst MarroneNaval Medical Research Center, Silver Spring, MD, USA.
Edgar NunezNaval Medical Research Center, Silver Spring, MD, USA.
Lindsey WhiteNaval Medical Research Center, Silver Spring, MD, USA.
Chad K PorterNaval Medical Research Center, Silver Spring, MD, USA.
Victor A SugihartoNaval Medical Research Center, Silver Spring, MD, USA.
Megan SchillingNaval Medical Research Center, Silver Spring, MD, USA.
Avinash S MahajanIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Charmagne BeckettNaval Medical Research Center, Silver Spring, MD, USA.
Alessandro SetteLa Jolla Institute for Immunology, La Jolla, CA, USA.
Stuart C SealfonIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Shane CrottyLa Jolla Institute for Immunology, La Jolla, CA, USA.
Andrew G LetiziaNaval Medical Research Center, Silver Spring, MD, USA.
Naval Medical Research Command · USLa Jolla Institute for Immunology · USHenry M. Jackson Foundation · USIcahn School of Medicine at Mount Sinai · USStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ongoing evolution of SARS-CoV-2 requires monitoring the capability of immune responses to cross-recognize Variants of Concern (VOC). In this cross-sectional study, we examined serological and cell-mediated immune memory to SARS-CoV-2 variants, including Omicron, among a cohort of 18-21-year-old Marines with a history of either asymptomatic or mild SARS-CoV-2 infection 6 to 14 months earlier. Among the 210 participants in the study, 169 were unvaccinated while 41 received 2 doses of mRNA-based COVID-19 vaccines. Vaccination of previously infected participants strongly boosted neutralizing and binding activity and memory B and T cell responses including the recognition of Omicron, compared to infected but unvaccinated participants. Additionally, no measurable differences were observed in immune memory in healthy young adults with previous symptomatic or asymptomatic infections, for ancestral or variant strains. These results provide mechanistic immunological insights into population-based differences observed in immunity against Omicron and other variants among individuals with different clinical histories.

Indexed as

Biological sciencesimmunologymicrobiology

Identifiers

PMID36168391
PMCPMC9502440
OpenAlexW4297015075

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.